NCT07123103View on ClinicalTrials.gov

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

February 29, 2028

Conditions

Solid Tumors

Interventions

DRUG

XB371

Intravenous (IV) infusion.

Trial Locations (2)

28078

RECRUITING

Exelixis Clinical Site #2, Huntersville

78229

RECRUITING

Exelixis Clinical Site #1, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY